As the calendar approaches the middle of November, a lineup of major companies across various sectors is set to report their ...

The Dow Jones Industrial Average, also known as the Dow, is one of the most popular stock market indexes, along with the S&P ...

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Outperform ...

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, ...

Wall Street stocks were firmly in the red early on Thursday as market participants were again zeroed in on Q3 earnings and a ...

In addition to Pfizer, Viking Therapeutics (VKTX), Roche, and Amgen, are all now developing weight loss meds. Novo Nordisk and Eli Lilly are also working on developing their own next-gen weight ...

The best 4K Blu-ray players deliver the ultimate picture quality for watching movies and TV series at home. Although streaming services are popular, Blu-rays deliver video at a higher bitrate ...